Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Driven by strong performance of Innovative Medicines, with double digit core Oplnc growth in the quarter Innovative Medicines Sandoz Group Q3 2021 Core operating 9M 2021 Net sales change vs. PY income 1 change vs. PY Core margin 1 Core margin 1 change vs. PY Net sales change vs. PY (in % cc) (in % cc) (%) (%pts cc) (in % cc) Core operating income 1 change vs. PY (in % cc) Core margin¹ Core margin 1 change vs. PY (%) (%pts cc) 7 13 37.8 1.9 6 8 37.1 0.9 -2 -15 23.8 -3.6 -4 -18 21.6 -3.7 5 9 34.3 1.0 4 4 33.3 0.1 1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 47 of the Condensed Interim Financial Report. 39 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation